Tarius SAC Tracker®
Background Analysis: US FDA Advisory Committee to Review Merck’s Bridion for Selective Reversal of Neuromuscular Blockage – MAR 18, 2015 (AADPAC)
This meeting was cancelled. The FDA stated that the reason for the cancellation is to allow time for the FDA to consider new information. The FDA will announce future meeting dates in the Federal Register, as needed. Tarius will monitor the Federal Register and other sources for any rescheduling or further announcements regarding this meeting.
The SAC Tracker report for this meeting is only available for SAC Tracker Premium subscribers.
The SAC Tracker reports are available for FREE on this site until 10 days after the meeting is held.
To obtain unlimited access to SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker Premium service.
METADATA: Sponsor: Organon USA, Merck Drug Name: sugammadex sodium injection Drug Class: selective relaxant binding agent Indication: reversal of moderate or deep neuromuscular blockade induced by rocuronium or vecuronium.